Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-04-23

FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application to introduce a Kisqali (ribociclib) and Femara (letrozole) co-packaged product, enabling combined use of the two drugs f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FEMARA (letrozole)
  • KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB)